nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—CYP2B6—malignant glioma	0.548	1	CbGaD
Fluoxetine—CYP1A2—Carmustine—malignant glioma	0.0839	0.57	CbGbCtD
Fluoxetine—CYP3A4—Temozolomide—malignant glioma	0.0634	0.431	CbGbCtD
Fluoxetine—HTR2C—choroid plexus—malignant glioma	0.0142	0.191	CbGeAlD
Fluoxetine—HTR2A—choroid plexus—malignant glioma	0.00713	0.096	CbGeAlD
Fluoxetine—ORM1—vertebral column—malignant glioma	0.00559	0.0752	CbGeAlD
Fluoxetine—HTR2C—telencephalic ventricle—malignant glioma	0.00416	0.0561	CbGeAlD
Fluoxetine—HTR2A—cerebellar cortex—malignant glioma	0.00359	0.0483	CbGeAlD
Fluoxetine—HTR2A—pons—malignant glioma	0.00254	0.0342	CbGeAlD
Fluoxetine—HTR2A—vertebral column—malignant glioma	0.00252	0.0339	CbGeAlD
Fluoxetine—HTR2A—telencephalic ventricle—malignant glioma	0.00209	0.0281	CbGeAlD
Fluoxetine—Paranoid reaction—Carmustine—malignant glioma	0.00196	0.0121	CcSEcCtD
Fluoxetine—Personality disorder—Carmustine—malignant glioma	0.00192	0.0119	CcSEcCtD
Fluoxetine—Pulmonary fibrosis—Carmustine—malignant glioma	0.00189	0.0117	CcSEcCtD
Fluoxetine—Pulmonary fibrosis—Temozolomide—malignant glioma	0.00183	0.0113	CcSEcCtD
Fluoxetine—HTR2A—pineal body—malignant glioma	0.00181	0.0244	CbGeAlD
Fluoxetine—Grand mal convulsion—Carmustine—malignant glioma	0.00175	0.0108	CcSEcCtD
Fluoxetine—Cerebral ischaemia—Temozolomide—malignant glioma	0.00166	0.0103	CcSEcCtD
Fluoxetine—Tongue discolouration—Temozolomide—malignant glioma	0.00166	0.0103	CcSEcCtD
Fluoxetine—Faecal incontinence—Carmustine—malignant glioma	0.00165	0.0102	CcSEcCtD
Fluoxetine—Faecal incontinence—Temozolomide—malignant glioma	0.00159	0.00982	CcSEcCtD
Fluoxetine—Cerebration impaired—Temozolomide—malignant glioma	0.00137	0.00843	CcSEcCtD
Fluoxetine—Myasthenia—Carmustine—malignant glioma	0.00132	0.00816	CcSEcCtD
Fluoxetine—Parosmia—Temozolomide—malignant glioma	0.00124	0.00764	CcSEcCtD
Fluoxetine—Paranoia—Carmustine—malignant glioma	0.00122	0.00752	CcSEcCtD
Fluoxetine—Thrombosis—Carmustine—malignant glioma	0.00118	0.00724	CcSEcCtD
Fluoxetine—Myopathy—Temozolomide—malignant glioma	0.00115	0.00707	CcSEcCtD
Fluoxetine—HTR2C—brainstem—malignant glioma	0.00113	0.0152	CbGeAlD
Fluoxetine—Apathy—Temozolomide—malignant glioma	0.00113	0.00694	CcSEcCtD
Fluoxetine—HTR2A—endothelium—malignant glioma	0.00112	0.0151	CbGeAlD
Fluoxetine—Flat affect—Temozolomide—malignant glioma	0.00112	0.00687	CcSEcCtD
Fluoxetine—Stupor—Carmustine—malignant glioma	0.00111	0.00687	CcSEcCtD
Fluoxetine—Scotoma—Carmustine—malignant glioma	0.0011	0.00675	CcSEcCtD
Fluoxetine—Menorrhagia—Temozolomide—malignant glioma	0.00109	0.00669	CcSEcCtD
Fluoxetine—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00109	0.00669	CcSEcCtD
Fluoxetine—SLC6A4—brainstem—malignant glioma	0.00107	0.0144	CbGeAlD
Fluoxetine—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00107	0.00658	CcSEcCtD
Fluoxetine—Herpes zoster—Temozolomide—malignant glioma	0.00107	0.00658	CcSEcCtD
Fluoxetine—Necrosis—Carmustine—malignant glioma	0.00106	0.00653	CcSEcCtD
Fluoxetine—Scotoma—Temozolomide—malignant glioma	0.00106	0.00652	CcSEcCtD
Fluoxetine—HTR2A—blood vessel—malignant glioma	0.00103	0.0139	CbGeAlD
Fluoxetine—Hyperaesthesia—Temozolomide—malignant glioma	0.00102	0.00631	CcSEcCtD
Fluoxetine—Memory impairment—Temozolomide—malignant glioma	0.00102	0.00631	CcSEcCtD
Fluoxetine—HTR2C—telencephalon—malignant glioma	0.001	0.0135	CbGeAlD
Fluoxetine—Petechiae—Temozolomide—malignant glioma	0.000977	0.00602	CcSEcCtD
Fluoxetine—Liver injury—Temozolomide—malignant glioma	0.000955	0.00589	CcSEcCtD
Fluoxetine—SLC6A4—telencephalon—malignant glioma	0.000948	0.0128	CbGeAlD
Fluoxetine—SIGMAR1—telencephalon—malignant glioma	0.000941	0.0127	CbGeAlD
Fluoxetine—SLC6A2—brainstem—malignant glioma	0.00094	0.0127	CbGeAlD
Fluoxetine—Accidental injury—Carmustine—malignant glioma	0.00094	0.00579	CcSEcCtD
Fluoxetine—Disturbance in attention—Temozolomide—malignant glioma	0.000928	0.00572	CcSEcCtD
Fluoxetine—Breast pain—Temozolomide—malignant glioma	0.000921	0.00568	CcSEcCtD
Fluoxetine—Amenorrhoea—Temozolomide—malignant glioma	0.000915	0.00564	CcSEcCtD
Fluoxetine—Thinking abnormal—Carmustine—malignant glioma	0.000909	0.0056	CcSEcCtD
Fluoxetine—Drug interaction—Carmustine—malignant glioma	0.000897	0.00553	CcSEcCtD
Fluoxetine—Leukocytosis—Carmustine—malignant glioma	0.000885	0.00546	CcSEcCtD
Fluoxetine—Herpes simplex—Temozolomide—malignant glioma	0.000872	0.00538	CcSEcCtD
Fluoxetine—Gait disturbance—Carmustine—malignant glioma	0.000852	0.00525	CcSEcCtD
Fluoxetine—Coordination abnormal—Carmustine—malignant glioma	0.000847	0.00522	CcSEcCtD
Fluoxetine—Neck pain—Carmustine—malignant glioma	0.000842	0.00519	CcSEcCtD
Fluoxetine—SLC6A2—telencephalon—malignant glioma	0.000835	0.0112	CbGeAlD
Fluoxetine—Pulmonary embolism—Carmustine—malignant glioma	0.000832	0.00513	CcSEcCtD
Fluoxetine—Gait disturbance—Temozolomide—malignant glioma	0.000824	0.00508	CcSEcCtD
Fluoxetine—Respiratory failure—Temozolomide—malignant glioma	0.000819	0.00505	CcSEcCtD
Fluoxetine—Coordination abnormal—Temozolomide—malignant glioma	0.000819	0.00505	CcSEcCtD
Fluoxetine—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000804	0.00495	CcSEcCtD
Fluoxetine—Vaginal inflammation—Temozolomide—malignant glioma	0.000804	0.00495	CcSEcCtD
Fluoxetine—Pulmonary embolism—Temozolomide—malignant glioma	0.000804	0.00495	CcSEcCtD
Fluoxetine—Depressed level of consciousness—Carmustine—malignant glioma	0.000803	0.00495	CcSEcCtD
Fluoxetine—Urinary incontinence—Carmustine—malignant glioma	0.000803	0.00495	CcSEcCtD
Fluoxetine—Candida infection—Carmustine—malignant glioma	0.000794	0.00489	CcSEcCtD
Fluoxetine—HTR2C—medulla oblongata—malignant glioma	0.000786	0.0106	CbGeAlD
Fluoxetine—Neuropathy—Carmustine—malignant glioma	0.000781	0.00481	CcSEcCtD
Fluoxetine—ORM1—spinal cord—malignant glioma	0.000779	0.0105	CbGeAlD
Fluoxetine—Urinary incontinence—Temozolomide—malignant glioma	0.000776	0.00478	CcSEcCtD
Fluoxetine—Depressed level of consciousness—Temozolomide—malignant glioma	0.000776	0.00478	CcSEcCtD
Fluoxetine—Candida infection—Temozolomide—malignant glioma	0.000767	0.00473	CcSEcCtD
Fluoxetine—Duloxetine—SLC6A3—malignant glioma	0.000766	0.502	CrCbGaD
Fluoxetine—Coma—Carmustine—malignant glioma	0.00076	0.00468	CcSEcCtD
Fluoxetine—Vaginal infection—Temozolomide—malignant glioma	0.000759	0.00468	CcSEcCtD
Fluoxetine—Aplastic anaemia—Temozolomide—malignant glioma	0.000755	0.00465	CcSEcCtD
Fluoxetine—Neuropathy—Temozolomide—malignant glioma	0.000755	0.00465	CcSEcCtD
Fluoxetine—Neoplasm—Carmustine—malignant glioma	0.000752	0.00464	CcSEcCtD
Fluoxetine—Gynaecomastia—Carmustine—malignant glioma	0.000744	0.00459	CcSEcCtD
Fluoxetine—Dry eye—Temozolomide—malignant glioma	0.000742	0.00458	CcSEcCtD
Fluoxetine—SIGMAR1—medulla oblongata—malignant glioma	0.00074	0.00996	CbGeAlD
Fluoxetine—Neoplasm—Temozolomide—malignant glioma	0.000727	0.00448	CcSEcCtD
Fluoxetine—Abnormal vision—Carmustine—malignant glioma	0.000725	0.00447	CcSEcCtD
Fluoxetine—Mental disability—Carmustine—malignant glioma	0.000722	0.00445	CcSEcCtD
Fluoxetine—HTR2C—midbrain—malignant glioma	0.000718	0.00967	CbGeAlD
Fluoxetine—Abnormal vision—Temozolomide—malignant glioma	0.000701	0.00432	CcSEcCtD
Fluoxetine—Phlebitis—Carmustine—malignant glioma	0.000701	0.00432	CcSEcCtD
Fluoxetine—HTR2C—spinal cord—malignant glioma	0.000701	0.00943	CbGeAlD
Fluoxetine—Mental disability—Temozolomide—malignant glioma	0.000698	0.0043	CcSEcCtD
Fluoxetine—Thrombophlebitis—Carmustine—malignant glioma	0.000698	0.0043	CcSEcCtD
Fluoxetine—Diabetes mellitus—Carmustine—malignant glioma	0.000694	0.00428	CcSEcCtD
Fluoxetine—Ear pain—Temozolomide—malignant glioma	0.000684	0.00422	CcSEcCtD
Fluoxetine—SLC6A4—midbrain—malignant glioma	0.000681	0.00916	CbGeAlD
Fluoxetine—ABCB1—blood vessel—malignant glioma	0.000678	0.00912	CbGeAlD
Fluoxetine—SIGMAR1—midbrain—malignant glioma	0.000676	0.0091	CbGeAlD
Fluoxetine—Thrombophlebitis—Temozolomide—malignant glioma	0.000674	0.00415	CcSEcCtD
Fluoxetine—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000671	0.00414	CcSEcCtD
Fluoxetine—Eye pain—Carmustine—malignant glioma	0.000669	0.00412	CcSEcCtD
Fluoxetine—SLC6A4—spinal cord—malignant glioma	0.000664	0.00894	CbGeAlD
Fluoxetine—SIGMAR1—spinal cord—malignant glioma	0.00066	0.00888	CbGeAlD
Fluoxetine—Gastroenteritis—Temozolomide—malignant glioma	0.000658	0.00406	CcSEcCtD
Fluoxetine—Injury—Carmustine—malignant glioma	0.000657	0.00405	CcSEcCtD
Fluoxetine—SLC6A2—medulla oblongata—malignant glioma	0.000656	0.00883	CbGeAlD
Fluoxetine—Vascular purpura—Temozolomide—malignant glioma	0.000652	0.00402	CcSEcCtD
Fluoxetine—Deafness—Temozolomide—malignant glioma	0.000652	0.00402	CcSEcCtD
Fluoxetine—Hepatic failure—Temozolomide—malignant glioma	0.000649	0.004	CcSEcCtD
Fluoxetine—Eye pain—Temozolomide—malignant glioma	0.000646	0.00398	CcSEcCtD
Fluoxetine—Amnesia—Carmustine—malignant glioma	0.000643	0.00396	CcSEcCtD
Fluoxetine—ORM1—central nervous system—malignant glioma	0.000632	0.00851	CbGeAlD
Fluoxetine—Hot flush—Temozolomide—malignant glioma	0.000624	0.00384	CcSEcCtD
Fluoxetine—Amnesia—Temozolomide—malignant glioma	0.000621	0.00383	CcSEcCtD
Fluoxetine—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000618	0.00381	CcSEcCtD
Fluoxetine—Menopausal symptoms—Temozolomide—malignant glioma	0.000618	0.00381	CcSEcCtD
Fluoxetine—HTR2A—embryo—malignant glioma	0.000617	0.0083	CbGeAlD
Fluoxetine—Thirst—Temozolomide—malignant glioma	0.000613	0.00378	CcSEcCtD
Fluoxetine—Hyponatraemia—Carmustine—malignant glioma	0.000606	0.00374	CcSEcCtD
Fluoxetine—Purpura—Temozolomide—malignant glioma	0.000605	0.00373	CcSEcCtD
Fluoxetine—Diplopia—Carmustine—malignant glioma	0.000604	0.00372	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000604	0.00372	CcSEcCtD
Fluoxetine—Diplopia—Temozolomide—malignant glioma	0.000584	0.0036	CcSEcCtD
Fluoxetine—Face oedema—Carmustine—malignant glioma	0.000583	0.00359	CcSEcCtD
Fluoxetine—Affect lability—Temozolomide—malignant glioma	0.000574	0.00354	CcSEcCtD
Fluoxetine—HTR2C—central nervous system—malignant glioma	0.000568	0.00765	CbGeAlD
Fluoxetine—Ataxia—Carmustine—malignant glioma	0.000568	0.0035	CcSEcCtD
Fluoxetine—HTR2A—brainstem—malignant glioma	0.000565	0.00761	CbGeAlD
Fluoxetine—Face oedema—Temozolomide—malignant glioma	0.000563	0.00347	CcSEcCtD
Fluoxetine—Liver function test abnormal—Carmustine—malignant glioma	0.000557	0.00344	CcSEcCtD
Fluoxetine—Mood swings—Temozolomide—malignant glioma	0.000553	0.00341	CcSEcCtD
Fluoxetine—Hypokalaemia—Carmustine—malignant glioma	0.00055	0.00339	CcSEcCtD
Fluoxetine—Ataxia—Temozolomide—malignant glioma	0.000549	0.00338	CcSEcCtD
Fluoxetine—HTR2A—retina—malignant glioma	0.000545	0.00734	CbGeAlD
Fluoxetine—Dehydration—Temozolomide—malignant glioma	0.000543	0.00334	CcSEcCtD
Fluoxetine—SLC6A4—central nervous system—malignant glioma	0.000539	0.00725	CbGeAlD
Fluoxetine—Dry skin—Temozolomide—malignant glioma	0.000535	0.0033	CcSEcCtD
Fluoxetine—Muscular weakness—Carmustine—malignant glioma	0.000533	0.00328	CcSEcCtD
Fluoxetine—Hypokalaemia—Temozolomide—malignant glioma	0.000531	0.00327	CcSEcCtD
Fluoxetine—Breast disorder—Temozolomide—malignant glioma	0.000527	0.00325	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000525	0.00324	CcSEcCtD
Fluoxetine—SIGMAR1—cerebellum—malignant glioma	0.000523	0.00704	CbGeAlD
Fluoxetine—Dysphagia—Carmustine—malignant glioma	0.000522	0.00322	CcSEcCtD
Fluoxetine—CYP2D6—brainstem—malignant glioma	0.000515	0.00693	CbGeAlD
Fluoxetine—Muscular weakness—Temozolomide—malignant glioma	0.000515	0.00317	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000515	0.00317	CcSEcCtD
Fluoxetine—Abdominal distension—Temozolomide—malignant glioma	0.000508	0.00313	CcSEcCtD
Fluoxetine—Dysphagia—Temozolomide—malignant glioma	0.000504	0.00311	CcSEcCtD
Fluoxetine—HTR2A—telencephalon—malignant glioma	0.000502	0.00675	CbGeAlD
Fluoxetine—Pancytopenia—Carmustine—malignant glioma	0.000496	0.00305	CcSEcCtD
Fluoxetine—Sweating increased—Temozolomide—malignant glioma	0.000491	0.00303	CcSEcCtD
Fluoxetine—Bronchitis—Temozolomide—malignant glioma	0.000485	0.00299	CcSEcCtD
Fluoxetine—Pancytopenia—Temozolomide—malignant glioma	0.000479	0.00295	CcSEcCtD
Fluoxetine—SLC6A2—central nervous system—malignant glioma	0.000474	0.00639	CbGeAlD
Fluoxetine—Dysuria—Temozolomide—malignant glioma	0.000472	0.00291	CcSEcCtD
Fluoxetine—Hyperglycaemia—Carmustine—malignant glioma	0.000471	0.0029	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000469	0.00289	CcSEcCtD
Fluoxetine—Pneumonia—Carmustine—malignant glioma	0.000468	0.00288	CcSEcCtD
Fluoxetine—Pollakiuria—Temozolomide—malignant glioma	0.000466	0.00287	CcSEcCtD
Fluoxetine—Erectile dysfunction—Temozolomide—malignant glioma	0.000464	0.00286	CcSEcCtD
Fluoxetine—Depression—Carmustine—malignant glioma	0.000464	0.00286	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Temozolomide—malignant glioma	0.00046	0.00284	CcSEcCtD
Fluoxetine—Weight increased—Temozolomide—malignant glioma	0.000459	0.00283	CcSEcCtD
Fluoxetine—Renal failure—Carmustine—malignant glioma	0.000457	0.00282	CcSEcCtD
Fluoxetine—CYP2D6—telencephalon—malignant glioma	0.000457	0.00615	CbGeAlD
Fluoxetine—Weight decreased—Temozolomide—malignant glioma	0.000456	0.00281	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Carmustine—malignant glioma	0.000456	0.00281	CcSEcCtD
Fluoxetine—Hyperglycaemia—Temozolomide—malignant glioma	0.000455	0.0028	CcSEcCtD
Fluoxetine—Stomatitis—Carmustine—malignant glioma	0.000454	0.0028	CcSEcCtD
Fluoxetine—Urinary tract infection—Carmustine—malignant glioma	0.000452	0.00279	CcSEcCtD
Fluoxetine—Pneumonia—Temozolomide—malignant glioma	0.000452	0.00279	CcSEcCtD
Fluoxetine—HTR2C—brain—malignant glioma	0.000451	0.00607	CbGeAlD
Fluoxetine—Depression—Temozolomide—malignant glioma	0.000448	0.00276	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000446	0.00275	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Temozolomide—malignant glioma	0.000441	0.00272	CcSEcCtD
Fluoxetine—ALB—brain—malignant glioma	0.00044	0.00593	CbGeAlD
Fluoxetine—Stomatitis—Temozolomide—malignant glioma	0.000438	0.0027	CcSEcCtD
Fluoxetine—Urinary tract infection—Temozolomide—malignant glioma	0.000437	0.00269	CcSEcCtD
Fluoxetine—SLC6A4—brain—malignant glioma	0.000428	0.00576	CbGeAlD
Fluoxetine—SIGMAR1—brain—malignant glioma	0.000425	0.00572	CbGeAlD
Fluoxetine—Sinusitis—Temozolomide—malignant glioma	0.000422	0.0026	CcSEcCtD
Fluoxetine—Haemoglobin—Carmustine—malignant glioma	0.00042	0.00259	CcSEcCtD
Fluoxetine—Haemorrhage—Carmustine—malignant glioma	0.000418	0.00257	CcSEcCtD
Fluoxetine—Hypoaesthesia—Carmustine—malignant glioma	0.000416	0.00256	CcSEcCtD
Fluoxetine—Hallucination—Carmustine—malignant glioma	0.000416	0.00256	CcSEcCtD
Fluoxetine—Oedema peripheral—Carmustine—malignant glioma	0.000412	0.00254	CcSEcCtD
Fluoxetine—Haemoglobin—Temozolomide—malignant glioma	0.000406	0.0025	CcSEcCtD
Fluoxetine—ABCB1—embryo—malignant glioma	0.000404	0.00544	CbGeAlD
Fluoxetine—Haemorrhage—Temozolomide—malignant glioma	0.000404	0.00249	CcSEcCtD
Fluoxetine—Hepatitis—Temozolomide—malignant glioma	0.000404	0.00249	CcSEcCtD
Fluoxetine—Visual impairment—Carmustine—malignant glioma	0.000403	0.00248	CcSEcCtD
Fluoxetine—Hypoaesthesia—Temozolomide—malignant glioma	0.000402	0.00248	CcSEcCtD
Fluoxetine—Hallucination—Temozolomide—malignant glioma	0.000402	0.00248	CcSEcCtD
Fluoxetine—Atomoxetine—SLC6A3—malignant glioma	0.000401	0.263	CrCbGaD
Fluoxetine—Pharyngitis—Temozolomide—malignant glioma	0.000401	0.00247	CcSEcCtD
Fluoxetine—Oedema peripheral—Temozolomide—malignant glioma	0.000398	0.00245	CcSEcCtD
Fluoxetine—HTR2A—medulla oblongata—malignant glioma	0.000394	0.00531	CbGeAlD
Fluoxetine—Visual impairment—Temozolomide—malignant glioma	0.000389	0.0024	CcSEcCtD
Fluoxetine—Erythema multiforme—Temozolomide—malignant glioma	0.000382	0.00235	CcSEcCtD
Fluoxetine—SLC6A2—brain—malignant glioma	0.000377	0.00507	CbGeAlD
Fluoxetine—Tinnitus—Temozolomide—malignant glioma	0.000376	0.00232	CcSEcCtD
Fluoxetine—Arrhythmia—Carmustine—malignant glioma	0.000373	0.0023	CcSEcCtD
Fluoxetine—Alopecia—Carmustine—malignant glioma	0.000369	0.00228	CcSEcCtD
Fluoxetine—Mental disorder—Carmustine—malignant glioma	0.000366	0.00226	CcSEcCtD
Fluoxetine—Malnutrition—Carmustine—malignant glioma	0.000364	0.00224	CcSEcCtD
Fluoxetine—Chills—Temozolomide—malignant glioma	0.000362	0.00223	CcSEcCtD
Fluoxetine—HTR2A—midbrain—malignant glioma	0.00036	0.00485	CbGeAlD
Fluoxetine—Orphenadrine—CYP2B6—malignant glioma	0.000359	0.236	CrCbGaD
Fluoxetine—ABCB1—retina—malignant glioma	0.000357	0.00481	CbGeAlD
Fluoxetine—Alopecia—Temozolomide—malignant glioma	0.000357	0.0022	CcSEcCtD
Fluoxetine—Mental disorder—Temozolomide—malignant glioma	0.000354	0.00218	CcSEcCtD
Fluoxetine—Back pain—Carmustine—malignant glioma	0.000352	0.00217	CcSEcCtD
Fluoxetine—HTR2A—spinal cord—malignant glioma	0.000351	0.00473	CbGeAlD
Fluoxetine—Malnutrition—Temozolomide—malignant glioma	0.000351	0.00217	CcSEcCtD
Fluoxetine—CYP2B6—central nervous system—malignant glioma	0.00035	0.0047	CbGeAlD
Fluoxetine—Dysgeusia—Temozolomide—malignant glioma	0.000344	0.00212	CcSEcCtD
Fluoxetine—Tremor—Carmustine—malignant glioma	0.000341	0.0021	CcSEcCtD
Fluoxetine—Back pain—Temozolomide—malignant glioma	0.00034	0.0021	CcSEcCtD
Fluoxetine—Anaemia—Carmustine—malignant glioma	0.000336	0.00207	CcSEcCtD
Fluoxetine—Agitation—Carmustine—malignant glioma	0.000334	0.00206	CcSEcCtD
Fluoxetine—Tremor—Temozolomide—malignant glioma	0.000329	0.00203	CcSEcCtD
Fluoxetine—ABCB1—telencephalon—malignant glioma	0.000329	0.00442	CbGeAlD
Fluoxetine—Ill-defined disorder—Temozolomide—malignant glioma	0.000326	0.00201	CcSEcCtD
Fluoxetine—Leukopenia—Carmustine—malignant glioma	0.000325	0.00201	CcSEcCtD
Fluoxetine—Anaemia—Temozolomide—malignant glioma	0.000325	0.002	CcSEcCtD
Fluoxetine—Agitation—Temozolomide—malignant glioma	0.000323	0.00199	CcSEcCtD
Fluoxetine—Angioedema—Temozolomide—malignant glioma	0.000321	0.00198	CcSEcCtD
Fluoxetine—Malaise—Temozolomide—malignant glioma	0.000317	0.00195	CcSEcCtD
Fluoxetine—Vertigo—Temozolomide—malignant glioma	0.000316	0.00195	CcSEcCtD
Fluoxetine—Convulsion—Carmustine—malignant glioma	0.000315	0.00194	CcSEcCtD
Fluoxetine—Leukopenia—Temozolomide—malignant glioma	0.000315	0.00194	CcSEcCtD
Fluoxetine—Hypertension—Carmustine—malignant glioma	0.000314	0.00194	CcSEcCtD
Fluoxetine—Palpitations—Temozolomide—malignant glioma	0.000311	0.00191	CcSEcCtD
Fluoxetine—Chest pain—Carmustine—malignant glioma	0.00031	0.00191	CcSEcCtD
Fluoxetine—Myalgia—Carmustine—malignant glioma	0.00031	0.00191	CcSEcCtD
Fluoxetine—Anxiety—Carmustine—malignant glioma	0.000309	0.0019	CcSEcCtD
Fluoxetine—Cough—Temozolomide—malignant glioma	0.000307	0.00189	CcSEcCtD
Fluoxetine—Convulsion—Temozolomide—malignant glioma	0.000304	0.00188	CcSEcCtD
Fluoxetine—Hypertension—Temozolomide—malignant glioma	0.000303	0.00187	CcSEcCtD
Fluoxetine—Confusional state—Carmustine—malignant glioma	0.000299	0.00184	CcSEcCtD
Fluoxetine—Myalgia—Temozolomide—malignant glioma	0.000299	0.00184	CcSEcCtD
Fluoxetine—Arthralgia—Temozolomide—malignant glioma	0.000299	0.00184	CcSEcCtD
Fluoxetine—Anxiety—Temozolomide—malignant glioma	0.000298	0.00184	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000297	0.00183	CcSEcCtD
Fluoxetine—Discomfort—Temozolomide—malignant glioma	0.000296	0.00182	CcSEcCtD
Fluoxetine—Infection—Carmustine—malignant glioma	0.000295	0.00182	CcSEcCtD
Fluoxetine—Dry mouth—Temozolomide—malignant glioma	0.000293	0.0018	CcSEcCtD
Fluoxetine—Thrombocytopenia—Carmustine—malignant glioma	0.000291	0.00179	CcSEcCtD
Fluoxetine—Tachycardia—Carmustine—malignant glioma	0.00029	0.00179	CcSEcCtD
Fluoxetine—Confusional state—Temozolomide—malignant glioma	0.000289	0.00178	CcSEcCtD
Fluoxetine—Anaphylactic shock—Temozolomide—malignant glioma	0.000287	0.00177	CcSEcCtD
Fluoxetine—HTR2A—central nervous system—malignant glioma	0.000285	0.00384	CbGeAlD
Fluoxetine—Infection—Temozolomide—malignant glioma	0.000285	0.00176	CcSEcCtD
Fluoxetine—Anorexia—Carmustine—malignant glioma	0.000283	0.00174	CcSEcCtD
Fluoxetine—Thrombocytopenia—Temozolomide—malignant glioma	0.000281	0.00173	CcSEcCtD
Fluoxetine—HTR2A—cerebellum—malignant glioma	0.000279	0.00375	CbGeAlD
Fluoxetine—Skin disorder—Temozolomide—malignant glioma	0.000279	0.00172	CcSEcCtD
Fluoxetine—CYP2B6—brain—malignant glioma	0.000278	0.00374	CbGeAlD
Fluoxetine—Hypotension—Carmustine—malignant glioma	0.000277	0.00171	CcSEcCtD
Fluoxetine—Hyperhidrosis—Temozolomide—malignant glioma	0.000277	0.00171	CcSEcCtD
Fluoxetine—Anorexia—Temozolomide—malignant glioma	0.000273	0.00169	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00027	0.00167	CcSEcCtD
Fluoxetine—Insomnia—Carmustine—malignant glioma	0.000268	0.00165	CcSEcCtD
Fluoxetine—Paraesthesia—Carmustine—malignant glioma	0.000266	0.00164	CcSEcCtD
Fluoxetine—Dyspnoea—Carmustine—malignant glioma	0.000265	0.00163	CcSEcCtD
Fluoxetine—CYP3A4—central nervous system—malignant glioma	0.000264	0.00355	CbGeAlD
Fluoxetine—Somnolence—Carmustine—malignant glioma	0.000264	0.00163	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000261	0.00161	CcSEcCtD
Fluoxetine—CYP2D6—central nervous system—malignant glioma	0.00026	0.0035	CbGeAlD
Fluoxetine—Insomnia—Temozolomide—malignant glioma	0.000259	0.0016	CcSEcCtD
Fluoxetine—ABCB1—medulla oblongata—malignant glioma	0.000258	0.00348	CbGeAlD
Fluoxetine—Decreased appetite—Carmustine—malignant glioma	0.000258	0.00159	CcSEcCtD
Fluoxetine—Paraesthesia—Temozolomide—malignant glioma	0.000258	0.00159	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Carmustine—malignant glioma	0.000256	0.00158	CcSEcCtD
Fluoxetine—Dyspnoea—Temozolomide—malignant glioma	0.000256	0.00158	CcSEcCtD
Fluoxetine—Somnolence—Temozolomide—malignant glioma	0.000255	0.00157	CcSEcCtD
Fluoxetine—CYP2D6—cerebellum—malignant glioma	0.000254	0.00342	CbGeAlD
Fluoxetine—Constipation—Carmustine—malignant glioma	0.000254	0.00156	CcSEcCtD
Fluoxetine—Pain—Carmustine—malignant glioma	0.000254	0.00156	CcSEcCtD
Fluoxetine—Dyspepsia—Temozolomide—malignant glioma	0.000252	0.00156	CcSEcCtD
Fluoxetine—Decreased appetite—Temozolomide—malignant glioma	0.000249	0.00154	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000248	0.00153	CcSEcCtD
Fluoxetine—Fatigue—Temozolomide—malignant glioma	0.000247	0.00152	CcSEcCtD
Fluoxetine—Pain—Temozolomide—malignant glioma	0.000245	0.00151	CcSEcCtD
Fluoxetine—Constipation—Temozolomide—malignant glioma	0.000245	0.00151	CcSEcCtD
Fluoxetine—Feeling abnormal—Carmustine—malignant glioma	0.000245	0.00151	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Carmustine—malignant glioma	0.000243	0.0015	CcSEcCtD
Fluoxetine—Feeling abnormal—Temozolomide—malignant glioma	0.000236	0.00146	CcSEcCtD
Fluoxetine—ABCB1—midbrain—malignant glioma	0.000236	0.00318	CbGeAlD
Fluoxetine—Body temperature increased—Carmustine—malignant glioma	0.000235	0.00145	CcSEcCtD
Fluoxetine—Abdominal pain—Carmustine—malignant glioma	0.000235	0.00145	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Temozolomide—malignant glioma	0.000235	0.00145	CcSEcCtD
Fluoxetine—ABCB1—spinal cord—malignant glioma	0.00023	0.0031	CbGeAlD
Fluoxetine—Urticaria—Temozolomide—malignant glioma	0.000228	0.0014	CcSEcCtD
Fluoxetine—Abdominal pain—Temozolomide—malignant glioma	0.000227	0.0014	CcSEcCtD
Fluoxetine—Body temperature increased—Temozolomide—malignant glioma	0.000227	0.0014	CcSEcCtD
Fluoxetine—HTR2A—brain—malignant glioma	0.000226	0.00305	CbGeAlD
Fluoxetine—Hypersensitivity—Carmustine—malignant glioma	0.000219	0.00135	CcSEcCtD
Fluoxetine—Asthenia—Carmustine—malignant glioma	0.000213	0.00131	CcSEcCtD
Fluoxetine—Hypersensitivity—Temozolomide—malignant glioma	0.000211	0.0013	CcSEcCtD
Fluoxetine—CYP2D6—brain—malignant glioma	0.000206	0.00278	CbGeAlD
Fluoxetine—Asthenia—Temozolomide—malignant glioma	0.000206	0.00127	CcSEcCtD
Fluoxetine—Diarrhoea—Carmustine—malignant glioma	0.000203	0.00125	CcSEcCtD
Fluoxetine—Pruritus—Temozolomide—malignant glioma	0.000203	0.00125	CcSEcCtD
Fluoxetine—Dizziness—Carmustine—malignant glioma	0.000196	0.00121	CcSEcCtD
Fluoxetine—Diarrhoea—Temozolomide—malignant glioma	0.000196	0.00121	CcSEcCtD
Fluoxetine—Dizziness—Temozolomide—malignant glioma	0.00019	0.00117	CcSEcCtD
Fluoxetine—Vomiting—Carmustine—malignant glioma	0.000189	0.00116	CcSEcCtD
Fluoxetine—Rash—Carmustine—malignant glioma	0.000187	0.00115	CcSEcCtD
Fluoxetine—Dermatitis—Carmustine—malignant glioma	0.000187	0.00115	CcSEcCtD
Fluoxetine—ABCB1—central nervous system—malignant glioma	0.000187	0.00251	CbGeAlD
Fluoxetine—Headache—Carmustine—malignant glioma	0.000186	0.00115	CcSEcCtD
Fluoxetine—ABCB1—cerebellum—malignant glioma	0.000183	0.00246	CbGeAlD
Fluoxetine—Vomiting—Temozolomide—malignant glioma	0.000182	0.00112	CcSEcCtD
Fluoxetine—Rash—Temozolomide—malignant glioma	0.000181	0.00111	CcSEcCtD
Fluoxetine—Dermatitis—Temozolomide—malignant glioma	0.000181	0.00111	CcSEcCtD
Fluoxetine—Headache—Temozolomide—malignant glioma	0.00018	0.00111	CcSEcCtD
Fluoxetine—Nausea—Carmustine—malignant glioma	0.000176	0.00109	CcSEcCtD
Fluoxetine—Nausea—Temozolomide—malignant glioma	0.00017	0.00105	CcSEcCtD
Fluoxetine—ABCB1—brain—malignant glioma	0.000148	0.002	CbGeAlD
Fluoxetine—HTR2A—Signaling Pathways—MMP3—malignant glioma	9.29e-06	0.000139	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CB—malignant glioma	9.27e-06	0.000138	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CAT—malignant glioma	9.22e-06	0.000137	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN2B—malignant glioma	9.21e-06	0.000137	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—BCHE—malignant glioma	9.21e-06	0.000137	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS1—malignant glioma	9.11e-06	0.000136	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SLC5A5—malignant glioma	9.1e-06	0.000136	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2B6—malignant glioma	9.07e-06	0.000135	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS1—malignant glioma	9.03e-06	0.000135	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	9e-06	0.000134	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—BCHE—malignant glioma	8.99e-06	0.000134	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTK2—malignant glioma	8.94e-06	0.000133	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NCOR1—malignant glioma	8.91e-06	0.000133	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCL8—malignant glioma	8.9e-06	0.000133	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL2—malignant glioma	8.9e-06	0.000133	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SLC5A5—malignant glioma	8.88e-06	0.000132	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TERT—malignant glioma	8.87e-06	0.000132	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HES1—malignant glioma	8.79e-06	0.000131	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	8.75e-06	0.00013	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NCOR1—malignant glioma	8.74e-06	0.00013	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NCOR1—malignant glioma	8.71e-06	0.00013	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PDGFB—malignant glioma	8.65e-06	0.000129	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—RAF1—malignant glioma	8.62e-06	0.000128	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGFR1—malignant glioma	8.61e-06	0.000128	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	8.6e-06	0.000128	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.52e-06	0.000127	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2—malignant glioma	8.51e-06	0.000127	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HIF1A—malignant glioma	8.48e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—BCHE—malignant glioma	8.47e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	8.44e-06	0.000126	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CB—malignant glioma	8.41e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—BCHE—malignant glioma	8.4e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SLC5A5—malignant glioma	8.37e-06	0.000125	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PDGFRA—malignant glioma	8.37e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SLC5A5—malignant glioma	8.29e-06	0.000124	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—IDH1—malignant glioma	8.29e-06	0.000124	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	8.28e-06	0.000123	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTT1—malignant glioma	8.24e-06	0.000123	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—malignant glioma	8.22e-06	0.000122	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CAV1—malignant glioma	8.2e-06	0.000122	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	8.18e-06	0.000122	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTP1—malignant glioma	8.16e-06	0.000122	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SPP1—malignant glioma	8.12e-06	0.000121	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KDR—malignant glioma	8.11e-06	0.000121	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—malignant glioma	8.09e-06	0.000121	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SPHK1—malignant glioma	8.02e-06	0.00012	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CAT—malignant glioma	7.94e-06	0.000118	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2C18—malignant glioma	7.86e-06	0.000117	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	7.84e-06	0.000117	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—F2—malignant glioma	7.81e-06	0.000116	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FN1—malignant glioma	7.81e-06	0.000116	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	7.77e-06	0.000116	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—malignant glioma	7.73e-06	0.000115	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS1—malignant glioma	7.72e-06	0.000115	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BAD—malignant glioma	7.71e-06	0.000115	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TERT—malignant glioma	7.7e-06	0.000115	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	7.69e-06	0.000115	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH1—malignant glioma	7.64e-06	0.000114	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PDGFB—malignant glioma	7.51e-06	0.000112	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NCOR1—malignant glioma	7.5e-06	0.000112	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CD80—malignant glioma	7.48e-06	0.000112	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGFR1—malignant glioma	7.48e-06	0.000111	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APC—malignant glioma	7.47e-06	0.000111	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CG—malignant glioma	7.47e-06	0.000111	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.43e-06	0.000111	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGF—malignant glioma	7.38e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HIF1A—malignant glioma	7.36e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTPN11—malignant glioma	7.34e-06	0.000109	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTP1—malignant glioma	7.33e-06	0.000109	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CAV1—malignant glioma	7.26e-06	0.000108	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—BCHE—malignant glioma	7.18e-06	0.000107	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—malignant glioma	7.15e-06	0.000107	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CAT—malignant glioma	7.13e-06	0.000106	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CAV1—malignant glioma	7.12e-06	0.000106	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CAV1—malignant glioma	7.1e-06	0.000106	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC5A5—malignant glioma	7.09e-06	0.000106	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KDR—malignant glioma	7.04e-06	0.000105	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BRAF—malignant glioma	7.02e-06	0.000105	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—malignant glioma	6.98e-06	0.000104	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CAT—malignant glioma	6.96e-06	0.000104	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT2—malignant glioma	6.83e-06	0.000102	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—malignant glioma	6.81e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.78e-06	0.000101	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FN1—malignant glioma	6.78e-06	0.000101	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—F2—malignant glioma	6.78e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—malignant glioma	6.74e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NCOR1—malignant glioma	6.73e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	6.7e-06	9.99e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BAD—malignant glioma	6.7e-06	9.98e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—malignant glioma	6.68e-06	9.96e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	6.64e-06	9.9e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH1—malignant glioma	6.63e-06	9.89e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—malignant glioma	6.62e-06	9.86e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NCOR1—malignant glioma	6.57e-06	9.8e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CD—malignant glioma	6.57e-06	9.79e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAT—malignant glioma	6.56e-06	9.78e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—malignant glioma	6.5e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAT—malignant glioma	6.5e-06	9.69e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CD80—malignant glioma	6.5e-06	9.69e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—malignant glioma	6.49e-06	9.67e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—malignant glioma	6.49e-06	9.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—malignant glioma	6.47e-06	9.64e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—malignant glioma	6.43e-06	9.58e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—malignant glioma	6.42e-06	9.57e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGF—malignant glioma	6.41e-06	9.56e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARG—malignant glioma	6.39e-06	9.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTPN11—malignant glioma	6.37e-06	9.5e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—malignant glioma	6.36e-06	9.48e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGF2—malignant glioma	6.29e-06	9.37e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARG—malignant glioma	6.24e-06	9.31e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—malignant glioma	6.21e-06	9.25e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NCOR1—malignant glioma	6.19e-06	9.23e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NCOR1—malignant glioma	6.14e-06	9.15e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CAV1—malignant glioma	6.11e-06	9.12e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—malignant glioma	6.1e-06	9.09e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS1—malignant glioma	5.96e-06	8.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT2—malignant glioma	5.93e-06	8.85e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—malignant glioma	5.91e-06	8.81e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	5.91e-06	8.81e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MDM2—malignant glioma	5.88e-06	8.77e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RAF1—malignant glioma	5.86e-06	8.74e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.84e-06	8.71e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—malignant glioma	5.82e-06	8.67e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—malignant glioma	5.8e-06	8.65e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.79e-06	8.64e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	5.72e-06	8.53e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—malignant glioma	5.71e-06	8.51e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	5.7e-06	8.5e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—malignant glioma	5.69e-06	8.48e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	5.65e-06	8.42e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—malignant glioma	5.58e-06	8.32e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—malignant glioma	5.57e-06	8.3e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAT—malignant glioma	5.56e-06	8.28e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—BCHE—malignant glioma	5.54e-06	8.26e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—malignant glioma	5.5e-06	8.2e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CAV1—malignant glioma	5.49e-06	8.18e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC5A5—malignant glioma	5.47e-06	8.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGF2—malignant glioma	5.46e-06	8.14e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARG—malignant glioma	5.38e-06	8.01e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CAV1—malignant glioma	5.36e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	5.31e-06	7.92e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—malignant glioma	5.26e-06	7.85e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—malignant glioma	5.26e-06	7.84e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NCOR1—malignant glioma	5.25e-06	7.82e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.24e-06	7.82e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—malignant glioma	5.24e-06	7.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	5.13e-06	7.65e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MDM2—malignant glioma	5.11e-06	7.62e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAF1—malignant glioma	5.09e-06	7.59e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—malignant glioma	5.07e-06	7.56e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAV1—malignant glioma	5.05e-06	7.53e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—malignant glioma	5.04e-06	7.51e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—malignant glioma	5.02e-06	7.49e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAV1—malignant glioma	5.01e-06	7.46e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—malignant glioma	5e-06	7.45e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—malignant glioma	4.98e-06	7.42e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	4.97e-06	7.41e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—malignant glioma	4.96e-06	7.39e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—malignant glioma	4.95e-06	7.37e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—malignant glioma	4.91e-06	7.32e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—malignant glioma	4.9e-06	7.3e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—malignant glioma	4.88e-06	7.28e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARG—malignant glioma	4.83e-06	7.19e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—malignant glioma	4.83e-06	7.19e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.78e-06	7.13e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—malignant glioma	4.78e-06	7.12e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARG—malignant glioma	4.71e-06	7.02e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	4.61e-06	6.88e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—malignant glioma	4.6e-06	6.86e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—malignant glioma	4.57e-06	6.82e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—malignant glioma	4.56e-06	6.8e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—malignant glioma	4.56e-06	6.8e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—malignant glioma	4.47e-06	6.66e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARG—malignant glioma	4.44e-06	6.62e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—malignant glioma	4.42e-06	6.59e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—malignant glioma	4.41e-06	6.57e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARG—malignant glioma	4.4e-06	6.56e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—malignant glioma	4.4e-06	6.55e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—malignant glioma	4.38e-06	6.53e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—malignant glioma	4.32e-06	6.44e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—malignant glioma	4.29e-06	6.4e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—malignant glioma	4.29e-06	6.4e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAT—malignant glioma	4.29e-06	6.39e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—malignant glioma	4.28e-06	6.38e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAV1—malignant glioma	4.28e-06	6.38e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—malignant glioma	4.27e-06	6.36e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—malignant glioma	4.23e-06	6.3e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—malignant glioma	4.19e-06	6.25e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—malignant glioma	4.11e-06	6.13e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.09e-06	6.09e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NCOR1—malignant glioma	4.05e-06	6.04e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—malignant glioma	4.04e-06	6.03e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—malignant glioma	4.02e-06	5.99e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—malignant glioma	4.01e-06	5.97e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—malignant glioma	3.9e-06	5.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—malignant glioma	3.88e-06	5.78e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—malignant glioma	3.84e-06	5.73e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—malignant glioma	3.83e-06	5.71e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—malignant glioma	3.8e-06	5.66e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—malignant glioma	3.8e-06	5.66e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARG—malignant glioma	3.76e-06	5.61e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—malignant glioma	3.74e-06	5.57e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—malignant glioma	3.71e-06	5.52e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—malignant glioma	3.69e-06	5.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—malignant glioma	3.57e-06	5.32e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—malignant glioma	3.52e-06	5.25e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—malignant glioma	3.49e-06	5.21e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—malignant glioma	3.49e-06	5.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—malignant glioma	3.49e-06	5.2e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	3.49e-06	5.2e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—malignant glioma	3.46e-06	5.16e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—malignant glioma	3.42e-06	5.11e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—malignant glioma	3.38e-06	5.03e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—malignant glioma	3.31e-06	4.94e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAV1—malignant glioma	3.3e-06	4.92e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—malignant glioma	3.3e-06	4.92e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—malignant glioma	3.23e-06	4.82e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—malignant glioma	3.09e-06	4.61e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—malignant glioma	3.05e-06	4.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	3.03e-06	4.52e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—malignant glioma	3.02e-06	4.5e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—malignant glioma	3.02e-06	4.5e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—malignant glioma	3.01e-06	4.48e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—malignant glioma	2.99e-06	4.45e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—malignant glioma	2.96e-06	4.41e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—malignant glioma	2.93e-06	4.37e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARG—malignant glioma	2.9e-06	4.33e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—malignant glioma	2.85e-06	4.25e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.64e-06	3.94e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—malignant glioma	2.6e-06	3.88e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—malignant glioma	2.58e-06	3.85e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—malignant glioma	2.52e-06	3.76e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—malignant glioma	2.48e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—malignant glioma	2.47e-06	3.68e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—malignant glioma	2.34e-06	3.48e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.3e-06	3.43e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—malignant glioma	2.28e-06	3.4e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—malignant glioma	2.28e-06	3.4e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.15e-06	3.2e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.13e-06	3.17e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—malignant glioma	2.13e-06	3.17e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—malignant glioma	1.99e-06	2.97e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—malignant glioma	1.91e-06	2.84e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—malignant glioma	1.86e-06	2.78e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.82e-06	2.71e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—malignant glioma	1.75e-06	2.62e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—malignant glioma	1.74e-06	2.59e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—malignant glioma	1.49e-06	2.22e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.4e-06	2.09e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—malignant glioma	1.15e-06	1.71e-05	CbGpPWpGaD
